Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis
1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission ...
Tag: Crohn’s Disease
Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2. ...
![ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis
1. Upadacitinib led to significantly greater percentages of clinical remission compared to placebo for both induction and maintenance studies. 2. ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...
Development of Anti-Drug Antibodies to Infliximab (Remicade®) and Adalimumab (Humira®) in Patients With Crohn’s Disease
1. Carriage of the HLA-DQA1*05 allele is significantly associated with the development of antibodies against anti-TNF agents. Evidence Rating Level: ...
Quick Take: Small Bowel Healing Detected by Endoscopy in Patients With Crohn’s Disease After Treatment With Antibodies Against Tumor Necrosis Factor
In patients with Crohn’s disease (CD), endoscopic evidence of healing after treatment is associated with favorable outcomes. Anti-tumor necrosis factor ...
